← Back to Search

Procedure

Virtual Heart Guided Ablation for Ventricular Tachycardia (AVERT-VT Trial)

N/A
Recruiting
Led By Jonathan Chrispin, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eligible patients must suffer from VT, thought to be secondary to structural heart disease (scarring).
Eligible patients must be at least 18 years old at the time of enrollment.
Must not have
Patients with Glomerular Filtration Rate (GFR) < 30 mL/min should not be enrolled in the study due to the use of intravenous gadolinium as an MRI contrast agent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new way to find the best places to zap during ablation procedures for people with VT. The goal is to make the procedure more effective and shorter.

Who is the study for?
This trial is for adults with a rapid heartbeat condition called Ventricular Tachycardia (VT) due to heart scarring. They must have had an MRI scan showing this scarring and be considered suitable for ablation therapy by their heart doctors. People with very poor kidney function, pregnant women, or those who can't undergo an MRI are excluded.
What is being tested?
The study tests a new 'virtual heart' imaging/simulation method to find the best spots in the heart to perform ablation on patients with VT. It aims to see if targeting these sites helps stop VT and reduces the time needed for the procedure.
What are the potential side effects?
While specific side effects aren't listed here, typical risks of ablation procedures include bleeding or infection at the catheter site, damage to blood vessels or heart tissue, irregular heartbeats, and rarely more serious complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have ventricular tachycardia due to heart scarring.
Select...
I am at least 18 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidney function is good enough for an MRI with contrast.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Tachycardia, Ventricular
Secondary study objectives
Freedom from Ventricular Tachycardia

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Virtual Heart Guided AblationExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,339 Previous Clinical Trials
14,881,736 Total Patients Enrolled
Jonathan Chrispin, MDPrincipal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
110 Total Patients Enrolled

Media Library

Virtual Heart Guided Ablation (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03536052 — N/A
Ventricular Tachycardia Research Study Groups: Virtual Heart Guided Ablation
Ventricular Tachycardia Clinical Trial 2023: Virtual Heart Guided Ablation Highlights & Side Effects. Trial Name: NCT03536052 — N/A
Virtual Heart Guided Ablation (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03536052 — N/A
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top